[go: up one dir, main page]

US20080287475A1 - 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer - Google Patents

4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer Download PDF

Info

Publication number
US20080287475A1
US20080287475A1 US12/091,382 US9138206A US2008287475A1 US 20080287475 A1 US20080287475 A1 US 20080287475A1 US 9138206 A US9138206 A US 9138206A US 2008287475 A1 US2008287475 A1 US 2008287475A1
Authority
US
United States
Prior art keywords
alkyl
cancer
amino
pyrazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/091,382
Other languages
English (en)
Inventor
Xiaomei Feng
Huiping Guan
Ying Kan
Stephanos Ioannidis
Bo Peng
Mei Su
Bin Wang
Tao Wang
Hai-Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US12/091,382 priority Critical patent/US20080287475A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IOANNIDIS, STEPHANOS, KAN, YING, PENG, BO, SU, MEI, WANG, BIN, GUAN, HUIPING, WANG, TAO, ZHANG, HAI-JUN, FENG, XIAOMEI
Publication of US20080287475A1 publication Critical patent/US20080287475A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel pyrazole derivatives, their pharmaceutical compositions and methods of use.
  • the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these pyrazole derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers.
  • RTK's Receptor tyrosine kinases
  • TTK's Receptor tyrosine kinases
  • Trk's are the high affinity receptors activated by a group of soluble growth factors called neurotrophins (NT).
  • the Trk receptor family has three members—TrkA, TrkB and TrkC.
  • NTs nerve growth factor
  • TrkA nerve growth factor
  • TrkB brain-derived growth factor
  • TrkC neurotrophins
  • NT3 neurotrophins
  • Each Trk receptor contains an extra-cellular domain (ligand binding), a trans-membrane region and an intra-cellular domain (including kinase domain).
  • the kinase Upon binding of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal transduction pathways.
  • Trk's are widely expressed in neuronal tissue during its development where Trk's are critical for the maintenance and survival of these cells.
  • Trk's play important role in both development and function of the nervous system (Patapoutian, A. et al Current Opinion in Neurobiology, 2001, 11, 272-280).
  • Trk inhibitors may yield a class of apoptosis-inducing agents specific for androgen-independent prostate cancer (Weeraratna, A. T. et al The Prostate, 2000, 45, 140-148).
  • Trk's are associated with secretory breast carcinoma ( Cancer Cell, 2002, 2, 367-376), colorectal cancer (Bardelli et al Science, 2003, 300, 949-949) and ovarian cancer (Davidson, B. et al Clinical Cancer Research, 2003, 9, 2248-2259).
  • Trk tyrosine kinase inhibitors Cephalon described CEP-751, CEP-701 (George, D. et al Cancer Research, 1999, 59, 2395-2341) and other indolocarbazole analogues (WO0114380) as Trk inhibitors. It was shown that CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKline disclosed certain oxindole compounds as Trk A inhibitors in WO0220479 and WO0220513.
  • Trk inhibitors JP2003231687A
  • Pfizer also recently published certain isothiazole Trk A inhibitors (Bioorg. Med. Chem. Lett. 2006, 16, 3444-3448).
  • Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO0250065, WO0262789, WO03027111 and WO200437814; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-1 receptor kinase (WO0348133). AstraZeneca have also reported Trk inhibitors in International Applications WO 2005/049033, WO 2005/103010, WO 2006/082392, WO 2006/087530, and WO 2006/087538.
  • JAK Janus-associated kinase
  • STAT signal transducers and activators or transcription
  • the JAK family consists of four non-receptor tyrosine kinases Tyk2, JAK1, JAK2, and JAK3, which play a critical role in cytokine- and growth factor mediated signal transduction. Cytokine and/or growth factor binding to cell-surface receptor(s), promotes receptor dimerization and facilitates activation of receptor-associated JAK by autophosphorylation. Activated JAK phosphorylates the receptor, creating docking sites for SH2 domain-containing signalling proteins, in particular the STAT family of proteins (STAT1, 2, 3, 4, 5a, 5b and 6). Receptor-bound STATs are themselves phosphorylated by JAKs, promoting their dissociation from the receptor, and subsequent dimerization and translocation to the nucleus.
  • the STATs bind DNA and cooperate with other transcription factors to regulate expression of a number of genes including, but not limited to, genes encoding apoptosis inhibitors (e.g. Bcl-XL, Mcl-1) and cell cycle regulators (e.g. Cyclin D1/D2, c-myc) (Haura et al., Nature Clinical Practice Oncology, 2005, 2(6), 315-324; Verna et al., Cancer and Metastasis Reviews, 2003, 22, 423-434).
  • apoptosis inhibitors e.g. Bcl-XL, Mcl-1
  • cell cycle regulators e.g. Cyclin D1/D2, c-myc
  • JAK2 JAK2 kinase domain with an oligomerization domain
  • TEL-JAK2, Bcr-JAK2 and PCM1-JAK2 translocations resulting in the fusion of the JAK2 kinase domain with an oligomerization domain, TEL-JAK2, Bcr-JAK2 and PCM1-JAK2
  • TEL-JAK2 JAK2 kinase domain with an oligomerization domain
  • Bcr-JAK2 and PCM1-JAK2 PCM1-JAK2
  • V617F valine-to-phenylalanine
  • JAKs in particular JAK3 play an important biological roles in the immunosuppressive field and there are reports of using JAK kinase inhibitors as tools to prevent organ transplant rejections (Changelian, P. S. et al, Science, 2003, 302, 875-878).
  • Merck Thimpson, J. E. et al Bioorg. Med. Chem. Lett. 2002, 12, 1219-1223
  • Incyte WO2005/105814
  • JAK inhibitors WO2005/105814
  • Recent Vertex described azaindoles as JAK inhibitors (WO2005/95400).
  • AstraZeneca have published quinoline-3-carboxamides as JAK3 inhibitors (WO2002/92571).
  • Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO2002/50065, WO2002/62789, WO2003/027111 and WO2004/37814; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-1 receptor kinase—WO2003/48133—and Trk in WO2005/049033 and WO2005/103010.
  • novel pyrazole compounds, or pharmaceutically acceptable salts thereof which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body.
  • the invention also relates to processes for the manufacture of said pyrazole compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man.
  • the applicants provide methods of using such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.
  • the properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis
  • Kaposi's sarcoma haemangioma
  • atheroma atherosclerosis
  • arterial restenosis autoimmune diseases
  • autoimmune diseases acute and chronic inflammation
  • bone diseases and ocular diseases with retinal vessel proliferation ocular diseases with retinal vessel proliferation.
  • the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers selected from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia
  • the applicants have further hereby discovered novel compounds, and pharmaceutically acceptable salts thereof, which possess JAK kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or pro-apoptotic activity and in methods of treatment of the human or animal body.
  • the invention also relates to processes for the manufacture of said compound, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing it and to its use in the manufacture of medicaments for use in the production of an anti-proliferation and/or pro-apoptotic effect in warm-blooded animals such as man.
  • the applicants provide methods of using said compound, or pharmaceutically acceptable salts thereof, in the treatment of myeloproliferative disorders, myelodysplastic syndrome and cancer.
  • the properties of the compounds claimed in this invention are expected to be of value in the treatment of myeloproliferative disorders, myelodysplastic syndrome, and cancer by inhibiting the tyrosine kinases, particularly the JAK family and more particularly JAK2.
  • Methods of treatment target tyrosine kinase activity, particularly the JAK family activity and more particularly JAK2 activity, which is involved in a variety of myeloproliferative disorders, myelodysplastic syndrome and cancer related processes.
  • inhibitors of tyrosine kinase are expected to be active against myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, idiopathic myelofibrosis, chronic myelomonocytic leukemia and hypereosinophilic syndrome, myelodysplastic syndromes and neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias, myelomas and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma.
  • Tyrosine kinase inhibitors, particularly the JAK family inhibitors and more particularly JAK2 inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to
  • the compound, or pharmaceutically acceptable salts thereof, of the invention is expected to be of value in the treatment or prophylaxis of against myeloproliferative disorders selected from chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, idiopathic myelofibrosis, chronic myelomonocytic leukemia and hypereosinophilic syndrome, myelodysplastic syndromes and cancers selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal
  • R 1 is selected from hydrogen, hydroxy, amino, mercapto, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino, 3-5-membered carbocyclyl or 3-5-membered heterocyclyl; wherein R 1 may be optionally substituted on carbon by one or more R 6 ; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
  • R 2 and R 3 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 -amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, (C 1-6 alky
  • R 4 is selected from cyano, carboxy, carbamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkanoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkoxycarbonyl, carbocyclyl or heterocyclyl; wherein R 4 may be optionally substituted on carbon by one or more R 10 ; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R 11 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, carbo
  • n 0, 1, 2 or 3; wherein the values of R 5 may be the same or different;
  • R 6 , R 8 , R 10 and R 12 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 al
  • R 7 , R 9 , R 11 , R 13 and R 15 are independently selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R 7 , R 9 , R 11 , R 13 and R 15 independently of each other may be optionally substituted on carbon by on or more R 16 ;
  • R 14 and R 16 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamin
  • R 17 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbon
  • R 19 and R 21 are independently selected from a direct bond, —O—, —N(R 22 )—, —C(O)—, —N(R 23 )C(O)—, —C(O)N(R 24 )—, —S(O) s —, —SO 2 N(R 25 )— or —N(R 26 )SO 2 —; wherein R 22 , R 23 , R 24 , R 25 and R 26 are independently selected from hydrogen or C 1-6 alkyl and s is 0-2;
  • R 18 is selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • the invention relates to compounds of formula (I), wherein: R 1 is selected from hydrogen, hydroxy, amino, mercapto, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino, 3-5-membered carbocyclyl or 3-5-membered heterocyclyl; wherein R 1 may be optionally substituted on carbon by one or more R 6 ; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
  • R 2 and R 3 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphony
  • R 4 is selected from cyano, carboxy, carbamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkanoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkoxycarbonyl, carbocyclyl or heterocyclyl; wherein R 4 may be optionally substituted on carbon by one or more R 10 ; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R 11 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, carbo
  • n 0, 1, 2 or 3; wherein the values of R 5 may be the same or different;
  • R 6 , R 8 , R 10 and R 12 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 al
  • R 7 , R 9 , R 11 , R 13 and R 15 are independently selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R 7 , R 9 , R 11 , R 13 and R 15 independently of each other may be optionally substituted on carbon by on or more R 16 ;
  • R 14 and R 16 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamin
  • R 17 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbon
  • R 19 and R 21 are independently selected from —O—, —N(R 22 )—, —C(O)—, —N(R 23 )C(O)—, —C(O)N(R 24 )—, —S(O) s —, —SO 2 N(R 25 )— or —N(R 26 )SO 2 —; wherein R 22 , R 23 , R 24 , R 25 and R 26 are independently selected from hydrogen or C 1-6 alkyl and s is 0-2;
  • R 18 is selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • the invention relates to compounds of formula (I), wherein: R 1 is selected from hydrogen, hydroxy, amino, mercapto, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, C 1-6 alkylsulphonylamino, 3-5-membered carbocyclyl or 3-5-membered heterocyclyl; wherein R 1 may be optionally substituted on carbon by one or more R 6 ; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R 7 ;
  • R 2 and R 3 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, N—(C 1-6 alkyl)
  • R 4 is selected from cyano, carboxy, carbamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkanoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkoxycarbonyl, carbocyclyl or heterocyclyl; wherein R 4 may be optionally substituted on carbon by one or more R 10 ; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R 11 ;
  • R 5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamino, carbo
  • n 0, 1, 2 or 3; wherein the values of R 5 may be the same or different;
  • R 6 , R 8 , R 10 and R 12 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 al
  • R 7 , R 9 , R 11 , R 13 and R 15 are independently selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R 7 , R 9 , R 11 , R 13 and R 15 independently of each other may be optionally substituted on carbon by on or more R 16 ;
  • R 14 and R 16 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphonylamin
  • R 17 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbon
  • R 19 and R 21 are independently selected from a direct bond, —O—, —N(R 22 )—, —C(O)—, —N(R 23 )C(O)—, —C(O)N(R 24 )—, —S(O) s —, —SO 2 N(R 25 )— or —N(R 26 )SO 2 —; wherein R 22 , R 23 , R 24 , R 25 and R 26 are independently selected from hydrogen or C 1-6 alkyl and s is 0-2;
  • R 18 is selected from C 1-6 alkyl, C 1-6 alkanoyl, C 1-6 alkylsulphonyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 1 is selected from C 1-6 alkyl, C 1-6 alkoxy, 3-5-membered carbocyclyl, and N,N—(C 1-6 alkyl) 2 amino, wherein R 1 may be optionally substituted on carbon by one or more R 6 ; and wherein R 6 is halo,
  • R 1 is C 1-6 alkoxy or 3-5-membered carbocyclyl.
  • R 1 is selected from C 1-6 alkyl, C 1-6 alkoxy or 3-5-membered carbocyclyl.
  • R 1 is C 1-6 alkyl or C 1-6 alkoxy.
  • R 1 is 3-5 membered carbocyclyl.
  • R 1 is N,N(C 1-6 alkyl) 2 amino.
  • R 1 is C 1-6 alkyl.
  • R 1 is C 1-4 alkyl.
  • R 1 is C 1-6 alkoxy.
  • R 1 is selected from methyl, methoxy, trifluoroethoxy, isopropoxy, cyclopropyl, and N,N-dimethylamino;
  • R 1 is isopropoxy or cyclopropyl.
  • R 1 is methyl, methoxy, isopropoxy or cyclopropyl.
  • R 1 is selected from methyl, methoxy, isopropoxy, N,N-dimethylamino, and cyclopropyl.
  • R 1 is isopropoxy
  • R 1 is methyl
  • R 1 is ethyl
  • R 1 is selected from methyl, ethyl, propyl, and butyl.
  • R 1 is selected from C 1-4 alkyl, C 1-4 alkoxy, and cyclopropyl.
  • R 1 is methoxy
  • R 1 is cyclopropyl.
  • R 1 is N,N-dimethylamino.
  • R 2 is selected from hydrogen, halo, nitro, and C 1-6 alkyl, wherein R 2 may be optionally substituted on carbon by one or more R 8 ; and wherein R 8 is halo.
  • R 2 is selected from hydrogen, chloro, fluoro, bromo, nitro, and trifluoromethyl.
  • R 2 is halo
  • R 2 is C 1-6 alkyl, wherein R 2 may be optionally substituted on carbon by one or more R 8 ; and wherein R 8 is halo.
  • R 2 and R 3 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, C 1-6 alkylsulphony
  • R 2 and R 3 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N—(C 1-6 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N—(C 1-6 alkyl)carbamoyl, N,N—(C 1-6 alkyl) 2 carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, N—(C 1-6 alkyl)sulphamoyl, N,N—(C 1-6 alkyl) 2 sulphamoyl, N—(C 1-6 alkyl)
  • R 2 and R 3 are independently selected from hydrogen, halo, N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino, or heterocyclyl-R 21 —; wherein R 21 is a direct bond.
  • R 2 and R 3 are independently selected from hydrogen and halo.
  • R 2 and R 3 are independently selected from hydrogen and chloro.
  • R 2 and R 3 are independently selected from hydrogen, fluoro, chloro, bromo, N-methyl-N-mesylamino and morpholino.
  • R 2 is halo and R 3 is hydrogen.
  • R 2 is chloro and R 3 is hydrogen.
  • R 2 is chloro or fluoro and R 3 is hydrogen.
  • R 3 is selected from hydrogen, halo, cyano, N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino, C 1-6 alkyl, (C 1-6 alkyl) 2 N—S(O) 2 —N(C 1-6 alkyl)-, and heterocyclyl-R 21 —, wherein R 3 may be optionally substituted on carbon by one or more R 8 ; wherein R 8 is halo; and wherein R 21 is a bond.
  • R 3 is hydrogen
  • R 3 is halo
  • R 3 is selected from N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino and (C 1-6 alkyl) 2 N—S(O) 2 —N(C 1-6 alkyl)-.
  • R 3 is selected from heterocyclyl-R 21 —, wherein R 3 may be optionally substituted on carbon by one or more R 5 ; wherein R 5 is halo; and wherein R 21 is a bond.
  • R 3 is selected from hydrogen, chloro, cyano, trifluoromethyl, (CH 3 ) 2 N—S(O) 2 —N(CH 3 )—, N-methyl-N-mesylamino, and morpholino.
  • R 3 is (CH 3 ) 2 N—S(O) 2 —N(CH 3 )—.
  • R 3 is N-methyl-N-mesylamino
  • R 3 is morpholino
  • R 4 is C 1-6 alkyl.
  • R 4 is methyl
  • R 5 is halo
  • R 5 is fluoro
  • n 1.
  • R 19 and R 21 are independently selected from —O—, —N(R 22 )—, —C(O)—, —N(l 23 )C(O)—, —C(O)N(R 24 )—, —S(O) s —, —SO 2 N(R 25 )— or —N(R 26 )SO 2 —; wherein R 22 , R 23 , R 24 , R 25 and R 26 are independently selected from hydrogen or C 1-6 alkyl and s is 0-2.
  • R 1 is selected from C 1-6 alkyl, C 1-6 alkoxy or 3-5-membered carbocyclyl;
  • R 1 and R 3 are independently selected from hydrogen, halo, N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino, or heterocyclyl-R 21 —;
  • R 4 is C 1-6 alkyl
  • R 5 is halo
  • n 1;
  • R 21 is a direct bond
  • R 1 is C 1-6 alkoxy
  • R 2 and R 3 are independently selected from hydrogen and halo
  • R 4 is C 1-6 alkyl
  • R 5 is halo
  • n 1;
  • R 1 is methyl, methoxy, isopropoxy or cyclopropyl
  • R 2 and R 3 are independently selected from hydrogen, fluoro, chloro, bromo, N-methyl-N-mesylamino and morpholino;
  • R 4 is methyl
  • R 5 is fluoro
  • n 1;
  • R 1 is selected from C 1-6 alkyl, C 1-6 alkoxy, 3-5-membered carbocyclyl, and N,N—(C 1-6 alkyl) 2 amino, wherein R 1 may be optionally substituted on carbon by one or more R 6 ;
  • R 2 is selected from hydrogen, halo, nitro, and C 1-6 alkyl, wherein R 2 may be optionally substituted on carbon by one or more R 8 ;
  • R 3 is selected from hydrogen, halo, cyano, N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino, C 1-6 alkyl, (C 1-6 alkyl) 2 N—S(O) 2 —N(C 1-6 alkyl)-, and heterocyclyl-R 21 —, wherein R 3 may be optionally substituted on carbon by one or more R 8 ;
  • R 4 is C 1-6 alkyl
  • R 5 is halo
  • R 6 is halo
  • R 8 is halo
  • R 21 is a bond
  • n 1;
  • R 1 is selected from methyl, methoxy, trifluoroethoxy, isopropoxy, cyclopropyl, and N,N-dimethylamino;
  • R 2 is selected from hydrogen, chloro, fluoro, bromo, nitro, and trifluoromethyl
  • R 3 is selected from hydrogen, chloro, cyano, trifluoromethyl, (CH 3 ) 2 N—S(O) 2 —N(CH 3 )—, N-methyl-N-mesylamino, and morpholino;
  • R 4 is methyl
  • R 5 is fluoro
  • n 1;
  • R 1 is selected from C 1-6 alkoxy, wherein R 1 may be optionally substituted on carbon by one or more R 6 ;
  • R 2 is selected from hydrogen and halo
  • R 3 is selected from hydrogen, halo, and heterocyclyl-R 21 —;
  • R 4 is C 1-6 alkyl
  • R 5 is halo
  • R 6 is halo
  • R 21 is a bond
  • n 1;
  • R 1 is selected from C 1-4 alkyl, C 1-4 alkoxy, and cyclopropyl;
  • R 2 is selected from hydrogen, halo, nitro, and C 1-6 alkyl, wherein R 2 may be optionally substituted on carbon by one or more R 8 ;
  • R 3 is selected from hydrogen, halo, cyano, N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino, C 1-6 alkyl, (C 1-6 alkyl) 2 N—S(O) 2 —N(C 1-6 alkyl)-, and heterocyclyl-R 21 —, wherein R 3 may be optionally substituted on carbon by one or more R 8 ;
  • R 4 is C 1-6 alkyl
  • R 5 is halo
  • R 6 is halo
  • R 8 is halo
  • R 21 is a bond
  • n 1;
  • preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.
  • preferred compounds of the invention are any one of:
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the inhibition of Trk activity.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders include fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial reste
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the production of an anti-proliferative effect.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the production of an pro-apoptotic effect in a warm-blooded animal such as man.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of myeloproliferative disorders, myelodysplastic syndrome, and cancer in a warm-blooded animal such as man.
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, idiopathic myelofibrosis, chronic myelomonocytic leukemia and hypereosinophilic syndrome, myelodysplastic syndromes and cancers selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal cancer
  • the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer, wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal cancer, lymphoma and leukaemia.
  • NSCLC non small cell lung cancer
  • SCLC small cell lung cancer
  • the present invention provides a method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation,
  • the present invention provides a method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for producing a pro-apoptotic effect in a warm-blooded animal, such as man, in need of such treatment, said method comprising administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically salt thereof.
  • the present invention provides a method of treating myeloproliferative disorders, myelodysplastic syndrome, and cancer in a warm-blooded animal, such as man, in need of such treatment, said method comprising administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, idiopathic myelofibrosis, chronic myelomonocytic leukemia and hypereosinophilic syndrome, myelodysplastic syndromes and cancers selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal cancer, lymphoma, and leukaemia in a warm-blooded animal, such as man, in need of
  • the present invention provides a method of treating myeloma, leukemia, ovarian cancer, breast cancer, and prostate cancer in a warm-blooded animal, such as man, in need of such treatment, said method comprising administering to said animal an effective amount of a compound of formula (I).
  • the present invention provides a method of treating myeloproliferative disorders, myelodysplastic syndrome and cancers (solid and hematologic tumors), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acromegaly, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating cancer in a warm-blooded animal, such as man, in need of such treatment, said method comprising administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal cancer, lymphoma and leukaemia.
  • NSCLC non small cell lung cancer
  • SCLC small cell lung cancer
  • the present invention provides a method of producing of a JAK inhibitory effect in a warm-blooded animal, such as man, in need of such treatment, said method comprising administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
  • cancers solid tumors and leukemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis,
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically-acceptable diluent or carrier, for use in the production of an pro-apoptotic effect in a warm-blooded animal such as man.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically-acceptable diluent or carrier, for use in the treatment of myeloproliferative disorders, myelodysplastic syndrome, and cancer in a warm-blooded animal such as man.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically-acceptable diluent or carrier, for use in the treatment of chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, idiopathic myelofibrosis, chronic myelomonocytic leukemia and hypereosinophilic syndrome, myelodysplastic syndromes and cancers selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent or carrier, for use in the treatment of myeloma, leukemia, ovarian cancer, breast cancer, and prostate cancer in a warm-blooded animal, such as man.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically-acceptable diluent or carrier, for use in the treatment of cancer, wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, mesothelioma, renal cancer, lymphoma and leukaemia in a warm blooded animal such as man.
  • NSCLC non small cell lung cancer
  • SCLC small cell lung cancer
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically-acceptable diluent or carrier, for use in the production of a JAK inhibitory effect in a warm blooded animal such as man.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the inhibition of Trk activity.
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man.
  • the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.
  • cancers solid tumours and leukaemia
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the production of an anti-proliferative effect.
  • Trk activity In one embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk A activity.
  • Trk activity In another embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk B activity.
  • the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi's sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer—non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma, leukaemia, tumours of the central and peripheral nervous system, melanoma
  • L is a displaceable group, suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.
  • Pyrimidines of formula (II) and pyrazole amine of formula (III) may be reacted together: a) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or N-methyl pyrrolid-2-one, optionally in the presence of a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid (or a suitable Lewis acid) and at a temperature in the range from 0° C. to reflux, particularly reflux; or b) under standard Buchwald conditions (for example see J. Am. Chem.
  • a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or N-methyl pyrrolid-2-one
  • a suitable acid for example an inorganic acid such as hydroch
  • L is a displaceable group as defined herein above.
  • Process c) may conveniently be carried out in a suitable solvent such as N-methylpyrrolidinone or butanol at a temperature in the range from 100-200° C., in particular in the range from 150-170° C.
  • a suitable base such as, for example, sodium methoxide or potassium carbonate.
  • Pg is a suitable nitrogen protecting group. Suitable values for Pg are defined below.
  • Process d) may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120° C., in particular in the range from 70-100° C.
  • a suitable solvent for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120° C., in particular in the range from 70-100° C.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only.
  • C 1-6 alkyl” and “C 1-4 alkyl” include methyl, ethyl, propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as ‘propyl’ are specific for the straight-chained version only and references to individual branched chain alkyl groups such as ‘isopropyl’ are specific for the branched-chain version only.
  • a similar convention applies to other radicals.
  • halo refers to fluoro, chloro, bromo and iodo.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a —CH 2 — group can optionally be replaced by a —C(O)—, and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • heterocyclyl examples and suitable values of the term “heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxopiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-N-oxide.
  • heterocyclyl is morpholino, piperazinyl and pyrrolidinyl.
  • a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a —CH 2 — group can optionally be replaced by a —C(O)— and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • a “3-5-membered heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 3, 4 or 5 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a —CH 2 — group can optionally be replaced by a —C(O)—, and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • Examples and suitable values of the term “3-5-membered heterocyclyl” are pyrrolyl, pyrrolinyl, imidazolyl, thiazolyl and furanyl.
  • a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a —CH 2 — group can optionally be replaced by a —C(O)—.
  • Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
  • Suitable values for “carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
  • a “3-5-membered carbocyclyl” is a saturated, partially saturated or unsaturated, monocyclic carbon ring that contains 3, 4 or 5 atoms; wherein a —CH 2 — group can optionally be replaced by a —C(O)—.
  • Suitable values for “3-5-membered carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl or cyclopentenyl.
  • C m-n or “C m-n group” used alone or as a prefix, refers to any group having m to n carbon atoms.
  • C 1-6 alkanoyloxy is acetoxy.
  • C 1-6 alkoxycarbonyl include C 1-4 alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
  • Examples of “C 1-6 alkoxy” include C 1-4 alkoxy, C 1-3 alkoxy, methoxy, ethoxy and propoxy.
  • Examples of “C 1-6 alkoxyimino” include C 1-4 alkoxyimino, C 1-3 alkoxyimino, methoxyimino, ethoxyimino and propoxyimino.
  • C 1-6 alkanoylamino examples include formamido, acetamido and propionylamino.
  • Examples of “C 1-6 alkylS(O) a wherein a is 0 to 2” include C 1-4 alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of “C 1-6 alkylthio” include methylthio and ethylthio.
  • Examples of “C 1-6 alkylsulphonylamino” examples include methylsulphonylamino and ethylsulphonylamino.
  • Examples of “C 1-6 alkanoyl” include C 1-4 alkanoyl, propionyl and acetyl.
  • Examples of “N—(C 1-6 alkyl)amino” include methylamino and ethylamino.
  • Examples of “N,N—(C 1-6 alkyl) 2 amino” include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino.
  • Examples of “C 2-6 alkenyl” are vinyl, allyl and 1-propenyl.
  • Examples of “C 2-6 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
  • N,N—(C 1-6 alkyl)sulphamoyl are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl.
  • N—(C 1-6 alkyl) 2 sulphamoyl are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl.
  • N—(C 1-6 alkyl)carbamoyl are N—(C 1-4 alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl.
  • N,N—(C 1-6 alkyl) 2 carbamoyl are N,N—(C 1-4 alkyl) 2 carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl.
  • Examples of “N—(C 1-6 alkyl)-N—(C 1-6 alkylsulphonyl)amino” are N-methyl-N-mesylamino and N-ethyl-N-mesylamino.
  • Examples of (C 1-6 alkyl) 2 N—S(O) 2 —NH— include (CH 3 ) 2 N—S(O) 2 —NH— and (CH 3 )(C 2 H 5 )N—S(O) 2 —NH—.
  • Examples of (C 1-6 alkyl)NH—S(O) 2 —NH— include (CH 3 )NH—S(O) 2 —NH— and (C 3 H 7 )NH—S(O) 2 —NH—.
  • Examples of (C 1-6 alkyl) 2 N—S(O) 2 —N(C 1-6 alkyl)- include (CH 3 ) 2 N—S(O) 2 —N(C 1-6 alkyl) and (CH 3 )(C 3 H 5 )N—S(O) 2 —N(C 2 H 5 )—.
  • Examples of (C 1-6 alkyl)NH—S(O) 2 —N(C 1-6 alkyl)- include (CH 3 )NH—S(O) 2 —N(CH 3 )— and (CH 3 )NH—S(O) 2 —N(C 2 H 5 ).
  • Examples of NH 2 —S(O) 2 —N(C 1-6 alkyl)- include NH 2 —S(O) 2 —N(CH 3 )— and NH 2 —S(O) 2 —N(C 3 H 7 ).
  • RT room temperature
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • the compounds claimed in this invention are capable of existing in different resonance structures and thus the compounds claimed herein include all possible resonance structures, for example optical isomers, diastereoisomers and geometric isomers and all tautomeric forms of the compounds of the formula (I).
  • Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
  • the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
  • An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention.
  • acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulf
  • Base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and so forth.
  • basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others.
  • Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.
  • the salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.
  • a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
  • composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier.
  • this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • Liquid form compositions include solutions, suspensions, and emulsions.
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical compositions can be in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • anti-cancer treatment may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
  • chemotherapy may include one or more of the following categories of anti-tumour agents:
  • antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention, or pharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
  • the compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
  • novel compounds, or pharmaceutically acceptable salts thereof, of this invention may be prepared using the reactions and techniques described herein.
  • the reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must then be used.
  • a microwave reaction vessel was charged with 1-(5-fluoropyrimidin-2-yl)ethanamine (Method 1, 0.25 g, 1.77 mmol), 2,5-dichloro-N-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidin-4-amine (Method 2, 0.50 g, 1.77 mmol), and DIPEA (0.30 g, 2.34 mmol).
  • Anhydrous n-BuOH (2 ml) was added, and the tube was sealed and heated in a microwave reactor at 160° C. for 10 hours.
  • Example 2 The title compounds were separated from Example 1 using the chiral HPLC system.
  • Enantiomeric excess for each individual enantiomer (e.e.): >99% calculated using area percent at 254 nm.
  • a microwave reaction vessel was charged with N- ⁇ 2,5-dichloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-4-yl ⁇ -N,N′,N′-trimethylsulfamide (Method 24, 83.9 mg, 0.221 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (Method 7, 78.4 mg, 0.443 mmol), and DIPEA (0.120 ml, 0.682 mmol). Anhydrous n-BuOH (1 ml) was added, and the tube was sealed and heated in a microwave reactor at 160° C. for 2 hours.
  • a microwave reaction vessel was charged with N- ⁇ 2,5-dichloro-6-[(5-methoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl ⁇ -N-methylmethanesulfonamide (Method 25, 63.8 mg, 0.174 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (Method 7, 61.7 mg, 0.348 mmol), and DIPEA (0.122 ml, 0.693 mmol). Anhydrous n-BuOH (1 ml) was added, and the tube was sealed and heated in a microwave reactor at 160° C. for 2 hours.
  • a microwave reaction vessel was charged with N- ⁇ 2-chloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-4-yl ⁇ -N,N′,N′-trimethylsulfamide (Method 30, 51.9 mg, 0.150 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (Method 7, 53.3 mg, 0.301 mmol), and DIPEA (0.079 ml, 0.449 mmol). Anhydrous n-BuOH (1 ml) was added, and the tube was sealed and heated in a microwave reactor at 180° C. for 4 hours.
  • a microwave reaction vessel was charged with N- ⁇ 2-chloro-5-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-4-yl ⁇ -N-methylmethanesulfonamide (Method 32, 111 mg, 0.332 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (Method 7, 143 mg, 0.668 mmol), and DIEA (0.250 ml, 1.44 mmol). Anhydrous n-BuOH (1 ml) was added, and the tube was sealed and heated in a microwave reactor at 160° C. for 2 hours.
  • a microwave reaction vessel was charged with N 3 -(2-chloro-5-fluoropyrimidin-4-yl)-N 5 ,N 5 -dimethyl-1H-pyrazole-3,5-diamine (Method 35, 50 mg, 0.2 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (Method 7, 50 mg, 0.23 mmol), and DIPEA (0.15 ml, 0.86 mmol) in n-BuOH (1 ml) was heated in a microwave reactor at 160° C. for 2 hours. Solvent was removed.
  • a microwave reaction vessel was charged with N 3 -(2,5-dichloropyrimidin-4-yl)-N 5 ,N 5 -dimethyl-1H-pyrazole-3,5-diamine (Method 36, 50 mg, 0.2 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (Method 7, 50 mg, 0.23 mmol), and DIPEA (0.15 ml, 0.86 mmol) in n-BuOH (1 ml) was heated in a microwave reactor at 160° C. for 2 hours. Solvent was removed.
  • a 10 ml microwave vial was charged with 2-chloro-5-fluoropyrimidine (2.0 g, 15.09 mmol), Pd 2 (dba) 3 (0.549 g, 0.6 mmol), DPPF (0.67 g, 1.21 mmol), zinc cyanide (1.15 g, 9.81 mmol), and zinc dust (0.237 mg, 3.62 mmol).
  • the flask was evacuated and backfilled with N 2 , and anhydrous dimethylacetamide.
  • the vial was mounted onto a Personal Chemistry microwave reactor and heated at 100° C. for 10 hours. The reaction mixture was diluted with EtOAc and then washed with brine three times. The organic layer was obtained and evaporated to dryness.
  • N-(1-(5-Fluoropyrimidin-2-yl)vinyl)acetamide (Method 12, 0.10 g, 0.55 mmol) in MeOH (5 ml) under N 2 was added (+)-1,2-bis((2S,5S)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I) trifluoromethanesulfonate (0.04 g, 0.0055 mmol).
  • the solution was transferred to a high pressure bomb and charged 150 psi H 2 . The reaction was stirred at room temperature for 4 hours.
  • Meth Compound m/z SM 15 2,5-Dichloro-N-(5- 271 5-cyclopropyl-1H- cyclopropyl-1H- pyrazol-3-amine pyrazol-3-yl)pyrimidin- and 2,4,5-trichloro- 4-amine pyrimidine 16 2-Chloro-N-(5-cyclopropyl- 254 5-cyclopropyl-1H- 1H-pyrazol-3-yl)-5- pyrazol-3-amine fluoropyrimidin-4-amine and 2,4-dichloro-5- fluoropyrimidine 17 2,6-Dichloro-N-(5-methyl- 245 5-methyl-1H-pyrazol- 1H-pyrazol-3-yl)pyrimidin- 3-amine and 4-amine 2,4,6-trichloro- pyrimidine
  • N-methyl-N-(2,5,6-trichloro-pyrimidin-4-yl)-methanesulfonamide (Method 19, 1.236 g, 4.3 mmol) in n-BuOH (8 ml) was added 5-isopropoxy-1H-pyrazol-3-ylamine (601 mg, 4.3 mmol) and ethyl-diisopropyl-amine (556 mg). The mixture was heated at 70° C. overnight. LC/MS showed the completion of the reaction. The solvent was evaporated and the residue was dissolved in DCM, which was then washed by aqueous NaHCO 3 , dried and concentrated.
  • N-(2,6-dichloro-5-fluoro-pyrimidin-4-yl)-N-methyl-methanesulfonamide (Method 21, 440 mg, 1.6 mmol) in n-BuOH (3 ml) was added 5-isopropoxy-1H-pyrazol-3-ylamine (227 mg, 1.6 mmol) and DIPEA (207 mg). The mixture was heated at 70° C. overnight. LC/MS showed the completion of the reaction. The solvent was evaporated and the residue was dissolved in DCM, which was then washed by aqueous NaHCO 3 , dried and concentrated. Flash chromatography was performed with EtOAc/Hex (50%) as eluent.
  • N,N,N′-trimethyl-N′-(2,5,6-trichloropyrimidin-4-yl)sulfamide (Method 26, 0.505 g, 1.59 mmol) in n-BuOH (3 ml) was added 5-methyl-1H-pyrazol-3-amine (159 mg, 1.59 mmol, 97% purity) and DIPEA (0.419 mL, 2.38 mmol). The mixture was heated at 50° C. overnight. LC/MS showed the completion of the reaction. The solvent was evaporated and the residue was partitioned between DCM and H 2 O. Then the organic layer was dried over Na 2 SO 4 , filtered to remove solid, then concentrated in vacuo.
  • N,N,N′-trimethyl-N′-(2,5,6-trichloropyrimidin-4-yl)sulfamide (Method 26, 318 mg, 1.0 mmol) in n-BuOH (1 ml) was added 5-methoxy-1H-pyrazol-3-amine (102 mg) and DIPEA (0.240 mL, 1.36 mmol). The mixture was heated at 50° C. overnight. The solvent was evaporated and the residue was partitioned between DCM and H 2 O. Then the organic layer was dried over Na 2 SO 4 , filtered to remove solid, then concentrated in vacuo.
  • N-(3-methoxy-1H-pyrazol-5-yl)-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-amine (240 mg) was dissolved in methylene chloride (5 mL), MCPBA (529 mg) was added. The resulting solution was stirred at room temperature for 0.5 hours and separate between methylene chloride and saturated sodium carbonate water solution. The organic layer was dried and solvent was removed under reduced pressure and low temperature. The crude product (270 mg) was carried on to do next step without further purification. m/z 338.
  • Method 51 may be used to obtain N-[(5-fluoropyrimidin-2-yl)methylene]-2-(S)-methylpropane-2-sulfinamide by replacing 2-(R)-methylpropane-2-sulfinamide with 2-(S)-methylpropane-2-sulfinamide as a starting material.
  • Method 52 may be used to obtain N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-(2S)-methylpropane-2-sulfinamide by replacing N-[(5-fluoropyrimidin-2-yl)methylene]-2-(R)-methylpropane-2-sulfinamide with N-[(5-fluoropyrimidin-2-yl)methylene]-2-(S)-methylpropane-2-sulfinamide as a starting material.
  • (S)-1-(5-Fluoropyrimidin-2-yl)ethanamine hydrochloride may also obtained using the process described in Method 53 by replacing N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-(2R-methylpropane-2-sulfinamide with N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-(2S)-methylpropane-2-sulfinamide as a starting material.
  • the compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Trks and more particularly Trk A and B.
  • Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more particularly Trk A and B activity, which is involved in a variety of cancer related processes.
  • inhibitors of tyrosine kinase are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma.
  • Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases.
  • the compounds of the invention are expected to be of value in the treatment or prophylaxis of cancers selected with up regulated of constitutively activated Trk kinases, including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusions proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotrophins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival signalling.
  • constitutively activated Trk kinases including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusions proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotrophins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival signalling.
  • Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B. These would be provided in commercial kits comprising a compound of this invention.
  • Trk A kinase activity was measured for its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using an Amplified Luminescent Proximity Assay (Alphascreen) technology (PerkinElmer, 549 Albany Street, Boston, Mass.).
  • Trk A kinase activity To measure Trk A kinase activity, the intracellular domain of a HIS-tagged human Trk A kinase (amino acids 442-796 of Trk A, Swiss-Prot Primary Accession Number P04629) was expressed in SF9 cells and purified using standard nickel column chromatography. After incubation of the kinase with a biotinylated substrate and adenosine triphosphate (ATP) for 20 minutes at room temperature, the kinase reaction was stopped by the addition of 30 mM ethylenediaminetetraacetic acid (EDTA).
  • EDTA ethylenediaminetetraacetic acid
  • reaction was performed in 384 well microtitre plates and the reaction products were detected with the addition of strepavidin coated Donor Beads and phosphotyrosine-specific antibodies coated Acceptor Beads using the EnVision Multilabel Plate Reader after an overnight incubation at room temperature.
  • Trk inhibitory activity of the following example was measured at the following IC 50 s.
  • the compounds of the present invention have utility for the treatment of myeloproliferative disorders, myelodysplastic syndrome and cancer by inhibiting the tyrosine kinases, particularly the JAK family and more particularly JAK2.
  • Methods of treatment target tyrosine kinase activity, particularly the JAK family activity and more particularly JAK2 activity, which is involved in a variety of myeloproliferative disorders, myelodysplastic syndrome and cancer related processes.
  • inhibitors of tyrosine kinase are expected to be active against myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, idiopathic myelofibrosis, chronic myelomonocytic leukemia and hypereosinophilic syndrome, myelodysplastic syndromes and neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias, myelomas and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma.
  • Tyrosine kinase inhibitors, particularly the JAK family inhibitors and more particularly JAK2 inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to
  • the compounds of the present invention have been shown to inhibit tyrosine kinases, particularly the JAK family and more particularly JAK2, as determined by the JAK2 Assay described herein.
  • the compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the JAK family and more particularly JAK2. These would be provided in commercial kits comprising a compound of this invention.
  • JAK2 kinase activity was measured for its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using an Amplified Luminescent Proximity Assay (Alphascreen) technology (PerkinElmer, 549 Albany Street, Boston, Mass.).
  • JAK2 kinase activity To measure JAK2 kinase activity, commercially available purified enzyme, C-terminal His6-tagged, recombinant, human JAK2, amino acids 808-end, (Genbank Accession number NM 004972) expressed by baculovirus in Sf21 cells from Upstate Biotechnology #14-640 was used. After incubation of the kinase with a biotinylated substrate and adenosine triphosphate (ATP) for 60 minutes at room temperature, the kinase reaction was stopped by the addition of 30 mM ethylenediaminetetraacetic acid (EDTA).
  • EDTA ethylenediaminetetraacetic acid
  • reaction was performed in 384 well microtitre plates and the reaction products were detected with the addition of streptavidin coated Donor Beads and phosphotyrosine-specific antibodies coated Acceptor Beads using the EnVision Multilabel Plate Reader after an overnight incubation at room temperature.
  • Peptide substrate TYK2 (Tyr 1054/1055 biotinylated peptide) Cell Signalling Technology #2200B. 402 uM stock. ATP Km 30 ⁇ M Assay conditions 150 pM JAK2 enzyme, 30 uM ATP, 80 nM Tyk2, 10 mM MgCl 2 , 50 mM Hepes buffer pH 7.5, 1 mM DTT, 0.025% DTT.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US12/091,382 2005-10-28 2006-10-26 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer Abandoned US20080287475A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/091,382 US20080287475A1 (en) 2005-10-28 2006-10-26 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73129905P 2005-10-28 2005-10-28
US60731299 2005-10-28
US80306106P 2006-05-24 2006-05-24
US60803061 2006-05-24
US12/091,382 US20080287475A1 (en) 2005-10-28 2006-10-26 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
PCT/GB2006/003978 WO2007049041A1 (fr) 2005-10-28 2006-10-26 Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu’inhibiteurs de tyrosine kinases dans le cadre d’un traitement anticancereux

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003978 A-371-Of-International WO2007049041A1 (fr) 2005-10-28 2006-10-26 Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu’inhibiteurs de tyrosine kinases dans le cadre d’un traitement anticancereux

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/713,695 Continuation US8088784B2 (en) 2005-10-28 2010-02-26 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Publications (1)

Publication Number Publication Date
US20080287475A1 true US20080287475A1 (en) 2008-11-20

Family

ID=37575154

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/091,382 Abandoned US20080287475A1 (en) 2005-10-28 2006-10-26 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
US12/713,695 Expired - Fee Related US8088784B2 (en) 2005-10-28 2010-02-26 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US13/308,584 Abandoned US20120071480A1 (en) 2005-10-28 2011-12-01 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/713,695 Expired - Fee Related US8088784B2 (en) 2005-10-28 2010-02-26 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US13/308,584 Abandoned US20120071480A1 (en) 2005-10-28 2011-12-01 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Country Status (22)

Country Link
US (3) US20080287475A1 (fr)
EP (2) EP1945631B8 (fr)
JP (1) JP2009513615A (fr)
KR (1) KR20080063846A (fr)
AR (1) AR056210A1 (fr)
AU (1) AU2006307657B2 (fr)
BR (1) BRPI0618011A2 (fr)
CA (1) CA2626375A1 (fr)
DK (1) DK1945631T3 (fr)
EC (1) ECSP088450A (fr)
ES (1) ES2391783T3 (fr)
HR (1) HRP20120824T1 (fr)
IL (1) IL190935A0 (fr)
MX (1) MX2008005398A (fr)
NO (1) NO20081893L (fr)
NZ (1) NZ567584A (fr)
PL (1) PL1945631T3 (fr)
PT (1) PT1945631E (fr)
RU (1) RU2463302C2 (fr)
TW (1) TW200800963A (fr)
UY (1) UY29886A1 (fr)
WO (1) WO2007049041A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111353A1 (en) * 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20080139561A1 (en) * 2005-02-04 2008-06-12 Astrazeneca Ab Pyrazolylaminopyridine Derivatives Useful as Kinases Inhibitors
US20080176872A1 (en) * 2005-02-16 2008-07-24 Astrazeneca Ab Chemical Compounds
US20100160325A1 (en) * 2005-10-28 2010-06-24 Astrazeneca Ab 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
US20100210648A1 (en) * 2005-05-16 2010-08-19 Astrazeneca R&D Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20100324040A1 (en) * 2007-05-04 2010-12-23 Astrazeneca Ab 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer
US20110183954A1 (en) * 2008-06-11 2011-07-28 Astrazeneca Ab Tricyclic 2,4-diamino-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US20110201628A1 (en) * 2008-09-30 2011-08-18 Astrazeneca Ab Heterocyclic jak kinase inhibitors
WO2016024230A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, et/ou d'un inhibiteur de bcl-2
WO2016024228A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques associant un inhibiteur de btk, un inhibiteur de pi3k, un inhibiteur de jak-2, un inhibiteur de pd-1 et/ou un inhibiteur de pd-l1
WO2017050938A1 (fr) 2015-09-25 2017-03-30 Astrazeneca Ab Composés et procédés d'inhibition de jak
WO2021041276A1 (fr) * 2019-08-23 2021-03-04 Development Center For Biotechnology Dérivés de pyrazole hétérocyclique en tant qu'inhibiteurs de tyrosine kinase du récepteur de type iii
EP4041241A1 (fr) 2019-09-27 2022-08-17 Disc Medicine, Inc. Procédés de traitement de la myélofibrose et d'affections associées
RU2833004C2 (ru) * 2019-08-23 2025-01-13 Дивелэпмэнт Сентэ Фо Байэутекнолэджи Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
US12365729B2 (en) 2020-05-13 2025-07-22 Disc Medicine, Inc. Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2426129T1 (sl) 2005-12-13 2017-02-28 Incyte Holdings Corporation Heteroarilno substituirani pirolo(2,3-b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janusove kinaze
EP2057140B1 (fr) 2006-08-24 2012-08-08 AstraZeneca AB Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives
WO2008061370A1 (fr) * 2006-11-24 2008-05-29 Mcmaster University Procédé de diagnostic permettant de détecter l'endométriose
CN101687863B (zh) * 2007-05-04 2012-09-12 阿斯利康(瑞典)有限公司 氨基-噻唑基-嘧啶衍生物及其治疗癌症的用途
MX342814B (es) 2007-06-13 2016-10-13 Incyte Holdings Corp Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
AU2008273891B2 (en) 2007-07-09 2012-01-12 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
WO2009007753A2 (fr) * 2007-07-11 2009-01-15 Astrazeneca Ab Composés chimiques 916-1
WO2009013545A2 (fr) * 2007-07-26 2009-01-29 Astrazeneca Ab Composés chimiques
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
AU2008321046B2 (en) 2007-11-16 2013-10-24 Incyte Holdings Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009095712A2 (fr) * 2008-01-29 2009-08-06 Astrazeneca Ab Composés chimiques
UY32055A (es) * 2008-08-19 2010-03-26 Astrazeneca Ab Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
CN102458581B (zh) 2009-05-22 2016-03-30 因塞特控股公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
HUE046493T2 (hu) 2009-05-22 2020-03-30 Incyte Holdings Corp 3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (fr) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine
WO2011028685A1 (fr) 2009-09-01 2011-03-10 Incyte Corporation Dérivés hétérocycliques de pyrazol-4-yl-pyrrolo[2,3-d] pyrimidines en tant qu'inhibiteurs de janus kinase
RS57219B1 (sr) 2010-03-10 2018-07-31 Incyte Holdings Corp Piperidin-4-il azetidin derivati kao inhibitori jak1
EP3087972A1 (fr) 2010-05-21 2016-11-02 Incyte Holdings Corporation Formulation topique pour un inhibiteur jak
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2012046882A1 (fr) 2010-10-07 2012-04-12 Takeda Pharmaceutical Company Limited Dérivés de 1,4-oxazépane
WO2012050141A1 (fr) * 2010-10-14 2012-04-19 住友化学株式会社 Composé à noyau hétéroaromatique et son utilisation pour la lutte contre les organismes nuisibles
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
PH12013502612A1 (en) 2011-06-20 2014-04-28 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2554544A1 (fr) * 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
HK1197232A1 (en) * 2011-08-25 2015-01-09 霍夫曼-拉罗奇有限公司 Serine/threonine pak1 inhibitors
WO2013033862A1 (fr) * 2011-09-05 2013-03-14 浙江海正药业股份有限公司 Dérivés 4-substitué-(3-substitué-1h-pyrazole-5-amino)-pyrimidines ayant une activité d'inhibition de protéine kinase et son utilisation
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2854248A1 (fr) * 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Derives de 2,4-diaminopyrimidine en tant qu'inhibiteurs de la serine/threonine kinase
WO2013173720A1 (fr) 2012-05-18 2013-11-21 Incyte Corporation Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
TW202228704A (zh) 2012-11-15 2022-08-01 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
BR122021015061B1 (pt) 2013-03-06 2022-10-18 Incyte Holdings Corporation Processos e intermediários para preparar um inibidor de jak
DK3030227T3 (da) 2013-08-07 2020-04-20 Incyte Corp Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3089832A1 (fr) 2018-01-30 2019-08-08 Incyte Corporation Procedes de preparation de (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
IL318069A (en) 2018-03-30 2025-02-01 Incyte Corp Using JAK inhibitors to treat hidradenitis suppurativa
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521453B2 (en) * 2001-12-07 2009-04-21 Astrazeneca Ab Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I)

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426180A1 (de) * 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (fr) * 1992-08-31 1999-04-13 Miguel A. Cacho Procede automatique a lit fluidise
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
AU726058B2 (en) 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT880508E (pt) 1996-02-13 2003-07-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP2001517146A (ja) * 1997-03-27 2001-10-02 グラツト ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 生産物の湿度を測定することにより、渦流流体層又は可動注入体内の顆粒化−、塊状化−、インスタント製品化−、コーティング−及び乾燥プロセス加工の監視及び／又は制御及び調整方法、並びに、前記方法を実施するためのエアエンジニアリング装置
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
WO2000014552A1 (fr) 1998-09-03 2000-03-16 Malcam Ltd. Dispositif servant a mesurer l'humidite au moyen de micro-ondes
US6227041B1 (en) 1998-09-17 2001-05-08 Cem Corporation Method and apparatus for measuring volatile content
BRPI9915552B8 (pt) 1998-11-10 2021-05-25 Janssen Pharmaceutica Nv pirimidinas inibidoras da reprodução do hiv
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001017995A1 (fr) 1999-09-10 2001-03-15 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
AU775360B2 (en) 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2001047897A1 (fr) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Inhibiteurs de la cytokine, en particulier de tnf-alpha
CA2400447C (fr) 2000-02-17 2008-04-22 Amgen Inc. Inhibiteurs de kinases
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
WO2001092224A1 (fr) 2000-05-31 2001-12-06 Astrazeneca Ab Derives d'indole possedant une activite endommageant les vaisseaux sanguins
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
KR20030027093A (ko) 2000-08-31 2003-04-03 화이자 프로덕츠 인크. 피라졸 유도체 및 단백질 키나제 억제제로서 그의 용도
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR20030032035A (ko) 2000-09-15 2003-04-23 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
MXPA03005610A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
EP1347971B1 (fr) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Inhibiteurs thiazolyl des tyrosine kinases de la famille tec
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
ATE491701T1 (de) * 2001-08-03 2011-01-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
MXPA04001087A (es) * 2001-08-03 2004-07-08 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
US7015231B2 (en) 2001-09-27 2006-03-21 Smithkline Beecham Corporation Chemical compounds
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
DE60331479D1 (de) * 2002-12-20 2010-04-08 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP4937112B2 (ja) 2004-03-30 2012-05-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MX337817B (es) * 2004-11-04 2011-11-04 Vertex Pharma Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
PT2383268E (pt) 2005-02-04 2015-12-21 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores de quinase
US8129403B2 (en) * 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
NZ561526A (en) 2005-02-16 2010-11-26 Astrazeneca Ab Pyrazole derivatives as Trk kinase inhibitors
WO2006115452A1 (fr) * 2005-04-27 2006-11-02 Astrazeneca Ab Utilisation des derives de la pyrazolyl-pyrimidine dans le traitement de la douleur
AU2006241825A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
US20080194606A1 (en) * 2005-05-05 2008-08-14 Astrazeneca Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
HRP20120824T1 (hr) * 2005-10-28 2012-11-30 Astrazeneca Ab Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma
BRPI0619706A2 (pt) * 2005-11-03 2011-10-11 Vertex Pharma composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar um distúrbio proliferativo num paciente, método para tratar cáncer num indivìduo
WO2008001070A1 (fr) * 2006-06-30 2008-01-03 Astrazeneca Ab Dérivés de pyrimidine utiles dans le traitement du cancer
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521453B2 (en) * 2001-12-07 2009-04-21 Astrazeneca Ab Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111353A1 (en) * 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20080139561A1 (en) * 2005-02-04 2008-06-12 Astrazeneca Ab Pyrazolylaminopyridine Derivatives Useful as Kinases Inhibitors
US8835465B2 (en) 2005-02-04 2014-09-16 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US8324252B2 (en) 2005-02-04 2012-12-04 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
US20080176872A1 (en) * 2005-02-16 2008-07-24 Astrazeneca Ab Chemical Compounds
US20100210648A1 (en) * 2005-05-16 2010-08-19 Astrazeneca R&D Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US8114989B2 (en) 2005-05-16 2012-02-14 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20100160325A1 (en) * 2005-10-28 2010-06-24 Astrazeneca Ab 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US8088784B2 (en) 2005-10-28 2012-01-03 Astrazeneca Ab 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
US20100324040A1 (en) * 2007-05-04 2010-12-23 Astrazeneca Ab 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer
US8486966B2 (en) 2007-05-04 2013-07-16 Astrazeneca Ab 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer
US20110183954A1 (en) * 2008-06-11 2011-07-28 Astrazeneca Ab Tricyclic 2,4-diamino-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US20110201628A1 (en) * 2008-09-30 2011-08-18 Astrazeneca Ab Heterocyclic jak kinase inhibitors
WO2016024230A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, et/ou d'un inhibiteur de bcl-2
WO2016024228A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques associant un inhibiteur de btk, un inhibiteur de pi3k, un inhibiteur de jak-2, un inhibiteur de pd-1 et/ou un inhibiteur de pd-l1
WO2016024231A1 (fr) 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1 et/ou d'un inhibiteur de pd-l1
WO2017050938A1 (fr) 2015-09-25 2017-03-30 Astrazeneca Ab Composés et procédés d'inhibition de jak
EP4219482A1 (fr) 2015-09-25 2023-08-02 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Composés et procédés d'inhibition de jak
WO2021041276A1 (fr) * 2019-08-23 2021-03-04 Development Center For Biotechnology Dérivés de pyrazole hétérocyclique en tant qu'inhibiteurs de tyrosine kinase du récepteur de type iii
EP4017853A4 (fr) * 2019-08-23 2023-08-30 Development Center for Biotechnology Dérivés de pyrazole hétérocyclique en tant qu'inhibiteurs de tyrosine kinase du récepteur de type iii
RU2833004C2 (ru) * 2019-08-23 2025-01-13 Дивелэпмэнт Сентэ Фо Байэутекнолэджи Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
US12448394B2 (en) 2019-08-23 2025-10-21 Development Center For Biotechnology Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors
EP4041241A1 (fr) 2019-09-27 2022-08-17 Disc Medicine, Inc. Procédés de traitement de la myélofibrose et d'affections associées
US12365729B2 (en) 2020-05-13 2025-07-22 Disc Medicine, Inc. Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

Also Published As

Publication number Publication date
RU2008120848A (ru) 2009-12-10
RU2463302C2 (ru) 2012-10-10
ES2391783T3 (es) 2012-11-29
US20100160325A1 (en) 2010-06-24
BRPI0618011A2 (pt) 2011-08-16
EP1945631B8 (fr) 2013-01-02
EP1945631A1 (fr) 2008-07-23
WO2007049041A8 (fr) 2012-11-01
WO2007049041A1 (fr) 2007-05-03
AU2006307657A1 (en) 2007-05-03
HRP20120824T1 (hr) 2012-11-30
ECSP088450A (es) 2008-06-30
MX2008005398A (es) 2008-09-24
US8088784B2 (en) 2012-01-03
JP2009513615A (ja) 2009-04-02
IL190935A0 (en) 2009-09-22
TW200800963A (en) 2008-01-01
AU2006307657B2 (en) 2010-10-28
DK1945631T3 (da) 2012-10-22
EP1945631B1 (fr) 2012-08-08
UY29886A1 (es) 2007-05-31
CA2626375A1 (fr) 2007-05-03
NO20081893L (no) 2008-05-20
PL1945631T3 (pl) 2012-12-31
KR20080063846A (ko) 2008-07-07
US20120071480A1 (en) 2012-03-22
NZ567584A (en) 2011-08-26
AR056210A1 (es) 2007-09-26
EP2388259A1 (fr) 2011-11-23
PT1945631E (pt) 2012-10-15

Similar Documents

Publication Publication Date Title
US8088784B2 (en) 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US8114989B2 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US7622482B2 (en) Chemical compounds
EP1853588B1 (fr) Composés chimiques
US8486966B2 (en) 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer
EP1686999B1 (fr) Derives de pyrazole en tant qu'inhibiteurs de recepteur tyrosine kinases
EP1846394B1 (fr) Dérivés de pyrazolylaminopyridine employés en tant qu'inhibiteurs de kinase
US20080194606A1 (en) Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
US20100204246A1 (en) 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
US20100204231A1 (en) Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
HK1113352B (en) Chemical compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FENG, XIAOMEI;GUAN, HUIPING;IOANNIDIS, STEPHANOS;AND OTHERS;REEL/FRAME:021536/0167;SIGNING DATES FROM 20080313 TO 20080325

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION